The Protein Labeling Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).


Learn More On The Protein Labeling Market:
https://www.thebusinessresearchcompany.com/report/protein-labelings-global-market-report

According to The Business Research Company’s Protein Labeling Global Market Report 2024, The protein labeling market size has grown rapidly in recent years. It will grow from $2.35 billion in 2023 to $2.58 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing demand for protein-based therapeutics, growing adoption of proteomics research, expanding range of applications for protein labeling, rising awareness of the benefits of protein labeling, increasing availability of skilled labor, increasing prevalence of chronic diseases.

The protein labeling market size is expected to see rapidly grown in the next few years. It will grow to $3.9 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to personalized medicine, point-of-care (poc) testing, growth in proteomics, increased funding and investment in life sciences, rising healthcare expenditure. Major trends in the forecast period include advances in protein labeling technologies, quantum dots and nanoparticles, multiplexing and high-throughput labeling, bioorthogonal labeling, integration of artificial intelligence (ai), sustainable labeling reagents, drug development.

Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labelling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labelling methods before separation and analysis are essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop, the identification of biomarkers that signal the presence of disease, or identification of genes or proteins responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3417&type=smp

The protein labeling market covered in this report is segmented –

1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies
2) By Labeling Method: In-vitro Labeling, In-vivo Labeling
3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the market. Janus kinase (JAK) inhibitors are orally administered small molecules that are emerging as a novel treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases: tofacitinib, baricitinib, and upadacitinib. Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase (JAK) inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In June 2020, AbbVie, a leading US-based pharmaceutical company, announced that it had applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor, with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The protein labeling market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis


Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model